Align Technology vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
San Jose clear aligner orthodontics inventor (NASDAQ: ALGN) at $3.23B 2024 revenue; 20 million Invisalign patient milestone Q1 2025 across 280,000+ doctors with iTero Lumina scanner competing with 3M Clarity for orthodontic clear aligner prescriptions.
About
Align Technology, Inc. is a San Jose, California-based global medical device company — publicly traded on NASDAQ (NASDAQ: ALGN) as an S&P 500 component — operating as the inventor of the Invisalign System and the world leader in clear aligner orthodontics, reaching 20 million Invisalign patients treated worldwide in Q1 2025 through a network of 280,000+ Invisalign-trained doctors across 100+ countries. In fiscal year 2024, Align reported $3.23 billion in total revenue with Q4 2024 revenue of $995.2 million (+4.0% year-over-year). Align's product portfolio comprises the Invisalign System of clear aligners, iTero intraoral digital scanners (including the iTero Lumina with 3X wider field of capture in a 50% smaller wand), and exocad CAD/CAM software for digital dental workflows. Manufacturing is based in Mexico with treatment planning performed in Costa Rica. CEO Joseph Hogan joined from GE Healthcare in 2015. Founded 1997 by Zia Chishti and Kelsey Wirth in San Jose.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.